

Current Challenges in Rare Disease Drug Development: Articulation of the Problem Statement

Kathleen M. Donohue, MD
Division of Gastroenterology and Inborn Errors Products (DGIEP)
U.S. Food and Drug Administration

Rare Disease Cures Accelerator Data & Analytics Platform September 17, 2019



Disclosure Statement

- No conflicts of interest
- Nothing to disclose
- This talk reflects the views of the author and should not be construed to represent FDA's views or policies
- In this talk "drug" refers to both drugs and biologics



Rare Disease Research?





Cures Accelerator





Patient Privacy & Data Security









- Patients
- Epidemiologists
- Geneticists
- Drug developers



What: Data

- Symptoms at diagnosis
- Molecular genetic diagnosis
- Predictors of clinical outcomes
- Background therapies
 - Diet, mobility assist devices, surgical procedures, respiratory support, etc.
- Time to events
- Endpoints
 - Mobile data
- Adverse Events




What: STROBE

- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies
- http://www.equator-network.org/reportingguidelines/strobe/



How: Data Standards



CDISC, MedDRA, audit trails, regulatory inspections

